Page 110 - 《中国药房》2021年23期
P. 110
[13] IBN SAIED W,MERCERON S,SCHWEBEL C,et al. with levofloxacin[J]. Pediatrics,2014,134(1):e146-e153.
Ventilator-associated pneumonia due to Stenotrophomo- [28] PATEL K,GOLDMAN J L. Safety concerns surrounding
nas maltophilia:risk factors and outcome[J]. J Infect, quinolone use in children[J]. J Clin Pharmacol,2016,56
2020,80(3):279-285. (9):1060-1075.
[14] HOTTA G,MATSUMURA Y,KATO K,et al. Risk fac- [29] 胡亚美,江载芳.诸福棠实用儿科学[M]. 7 版.北京:人民
tors and outcomes of Stenotrophomonas maltophilia bacte- 卫生出版社,2010:874-892.
raemia:a comparison with bacteraemia caused by Pseudo- [30] JAMES E F. Martindale:the extra pharmacopoeia[M].
monas aeruginosa and Acinetobacter species[J]. PLoS 31st edition. London:Royal Pharmaceutical Society,
One,2014,9(11):e112208. 2000:129-298.
[15] 胡付品,郭燕,朱德妹,等. 2020 年 CHINET 中国细菌耐 [31] TANDAN M,CORMICAN M,VELLINGA A. Adverse
药监测[J].中国感染与化疗杂志,2021,21(4):377-387. events of fluoroquinolones vs. other antimicrobials pre-
[16] HANG Y T,LIN C Y,CHEN Y H,et al. Update on infec- scribed in primary care:a systematic review and me-
tions caused by Stenotrophomonas maltophilia with parti- ta-analysis of randomized controlled trials[J]. Int J Antimi-
cular attention to resistance mechanisms and therapeutic crob Agents,2018,52(5):529-540.
options[J]. Front Microbiol,2015,2(6):893. [32] COUTINHO A E,CHAPMAN K E. The anti-inflammatory
[17] KO J H,KANG C I,CORNEJO-JUÁREZ P E T,et al. and immunosuppressive effects of glucocorticoids,recent
Fluoroquinolones versus trimethoprim-sulfamethoxazole developments and mechanistic insights[J]. Mol Cell Endo-
for the treatment of Stenotrophomonas maltophilia infec- crinol,2011,335(1):2-13.
tions:a systematic review and meta-analysis[J]. Clin [33] TÉBLICK A,PEETERS B,LANGOUCHE L,et al. Adre-
Microbiol Infect,2019,25(5):546-554. nal function and dysfunction in critically ill patients[J].
[18] CHIEN S,WELLS T G,BLUMER J L,et al. Levofloxa- Nat Rev Endocrinol,2019,15(7):417-427.
cin pharmacokinetics in children[J]. J Clin Pharmacol, [34] ANNANE D. Corticosteroids for severe sepsis:an evi-
2005,45(2):153-160. dence-based guide for physicians[J]. Ann Intensive Care,
[19] ZHOU L,BAO J,MA J. Hemolytic anemia and reactive 2011,1(1):7.
thrombocytosis associated with cefoperazone/sulbactam[J]. [35] WEISS S L,FITZGERALD J C,PAPPACHAN J,et al.
Front Pharmacol,2019,10:1342. Global epidemiology of pediatric severe sepsis:the sepsis
[20] REN X,LIU D,DING N,et al. Safety evaluation of cepha- prevalence,outcomes,and therapies study[J]. Am J Respir
losporins based on utilization and adverse drug events: Crit Care Med,2015,191(10):1147-1157.
analysis of two databases in China[J]. Expert Opin Drug [36] EL-NAWAWY A,KHATER D,Omar H,et al. Evaluation
Saf,2012,11(5):689-697. of early corticosteroid therapy in management of pediatric
[21] 谢悦良,贾素洁,刘晶晶,等.治疗药物监测在头孢哌酮钠 septic shock in pediatric intensive care patients:a rando-
舒巴坦致脑病诊疗中的应用[J].中国新药与临床杂志, mized clinical study[J]. Pediatr Infect Dis J,2017,36(2):
2019,38(6):378-381. 155-159.
[22] 李燕,孙冲,吕萌,等.头孢哌酮钠舒巴坦钠的儿童药品不 [37] ZIMMERMAN J J. Adjunctive steroid therapy for treat-
良反应分析[J/OL].中国药物警戒,2021(2021-06-28) ment of pediatric septic shock[J]. Pediatr Clin North Am,
[2021-07-11]. http://kns.cnki.net/kcms/detail/11.5219.R. 2017,64(5):1133-1146.
20210628.1556.004.html. [38] ROCHWERG B,OCZKOWSKI S J,SIEMIENIUK R A C,
[23] BEUMIER M,CASU G S,HITES M,et al. Elevated β- et al. Corticosteroids in sepsis:an updated systematic
lactam concentrations associated with neurological deterio- review and meta-analysis[J]. Crit Care Med,2018,46(9):
ration in ICU septic patients[J]. Minerva Anestesiol,2015, 1411-1420.
81(5):497-506. [39] RHODES A,EVANS L E,ALHAZZANI W,et al. Survi-
[24] FUGATE J E,KALIMULLAH E A,HOCKER S E,et al. ving sepsis campaign:international guidelines for manage-
Cefepime neurotoxicity in the intensive care unit:a cause ment of sepsis and septic shock:2016[J]. Intensive Care
of severe,underappreciated encephalopathy[J]. Crit Care, Med,2017,43(3):304-377.
2013,17(6):264. [40] LAVIOLLE B,ANNANE D,FOUGEROU C,et al. Gluco
[25] BHATTACHARYYA S,DARBY R R,RAIBAGKAR P, and mineralocorticoid biological effects of a 7-day treat-
et al. Antibiotic-associated encephalopathy[J]. Neurology, ment with low doses of hydrocortisone and fludrocorti-
2016,86(10):963-971. sone in septic shock[J]. Intensive Care Med,2012,38(8):
[26] 孔钦翔,张照如,李家斌.抗菌药物相关性脑病研究进 1306-1314.
展[J].中国抗生素杂志,2017,42(7):621-625. (收稿日期:2021-04-06 修回日期:2021-09-07)
[27] BRADLEY J S,KAUFFMAN R E,BALIS D A,et al. As- (编辑:刘明伟)
sessment of musculoskeletal toxicity 5 years after therapy
·2916 · China Pharmacy 2021 Vol. 32 No. 23 中国药房 2021年第32卷第23期